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Introduction: Lafora body disease (LBD) is a rare autosomal recessive disorder characterized by progression to inex-
orable dementia and frequent occipital seizures, in addition to myoclonus and generalized tonic–clonic seizures
(GTCSs). It belongs to the group of progressive myoclonus epilepsies (PMEs), rare inherited neurodegenerative
diseases with great clinical and genetic differences, as well as poor prognosis. Since those patients have a
pharmacoresistant disease, an adjunctive treatment option is vagus nerve stimulation (VNS). To date, there are
four reported cases of the utility of VNS in PME — in Unverricht–Lundborg disease (ULD), myoclonic epilepsy
with ragged-red ﬁbers (MERRF), Gaucher's disease, and in one case that remained unclassiﬁed.
Case presentation: A 19-year-old male patient had progressive myoclonus, GTCSs that often progressed to status
epilepticus (SE), progressive cerebellar and extrapyramidal symptomatology, and dementia, and his disease was
pharmacoresistant. We conﬁrmed the diagnosis of LBD by genetic testing. After VNS implantation, in the one-
year follow-up period, there was a complete reduction of GTCS and SE, signiﬁcant regression of myoclonus, and
moderate regression of cerebellar symptomatology.
Conclusion: To our knowledge, this is the ﬁrst reported case of the utility of VNS in LBD. Vagus nerve stimulation
therapy may be considered a treatment option for different clinical entities of PME. Further studies with a larger
number of patients are needed.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Lafora body disease (LBD) is a rare autosomal recessive disorder ﬁrst
described by Lafora and Gluelkin in 1911, with onset between the ages
of 10 and 18 years, characterized by progression to inexorable dementia
and frequent occipital seizures, in addition tomyoclonus and generalized
tonic–clonic seizures (GTCSs). Distinctive features of the disease include
polyglucosan inclusions (Lafora bodies) in the neurons and various
other tissues, including the skin, the skeletal muscles, and the heart.
The disease is connectedwithmutation of the two genes located on chro-
mosome 6q24, involved in the glycogenmetabolismof EPM2A (encoding
protein tyrosine phosphatase — laforin) and EPM2B (encoding proteinsek), zpetelin@mef.hr
ovic@gmail.com (S. Nankovic),
l.com (K. Gotovac),
il.com (I. Kovacevic),
c. Open access under CC BY-NC-ND liceubiquitin ligase —malin). Recently, a mutation of the third gene EPM2C
has also been identiﬁed [1].
Lafora body disease belongs to the group of progressive myoclonus
epilepsies (PME), rare inherited neurodegenerative diseases with
poor prognosis that account for around 1% of epilepsy cases at specialist
centers. Progressivemyoclonus epilepsies encompass different diagnos-
tic entities and common causes. Besides LBD, they include Unverricht–
Lundborg disease (ULD), myoclonic epilepsy with ragged-red ﬁbers
(MERRF), neuronal ceroid lipofuscinoses, sialidoses, and dentatorubral-
pallidoluysian atrophy [2,3]. Since those patients have a pharmaco-
resistant disease and are not candidates for resective neurosurgical treat-
ment, adjunctive treatment options are vagus nerve stimulation (VNS)
and subthalamic deep brain stimulation (DBS) [4]. To date, there are
four reported cases of the utility of VNS in PME — in ULD, MERRF,
Gaucher's disease type III, and one case that remained unclassiﬁed (the
last patient also underwent DBS after VNS) [5–7]. We report a ﬁrst case,
to our knowledge, of the utility of VNS in LBD.
2. Case presentation
A 19-year-old patient was hospitalized for the ﬁrst time at our hos-
pital in May 2012. Disease onset was at the age of 16, with occipital el-
ementary partial seizures and bilateral handmyoclonus that, after a fewnse.
Table 1
Nucleotide sequence of the primers used for PCR ampliﬁcation.
Primer Sequence
EPM2B F1 5′-TGACCATGACTGTGACCGTGA-3′
EPM2B F2 5′-GGTGCTGCACCTCATAGAGCT-3′
EPM2B F3 5′-ATGTCACCATCACCAACGACT-3′
EPM2B F4 5′-TCAAGTATGCAGCTTGTCGGC-3′
EPM2B R1 5′-GCTGAGCCCAGGAGCTCTATG-3′
EPM2B R2 5′-GACAACCACATGGCAGTCGTT-3′
EPM2B R3 5′-AGGTATCCACTTGGCCGACAA-3′
EPM2B R4 5′-AACAATTCATTAATGGCAGCACTAGTG-3′
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basis, often in clusters (provoked with sleep deprivation and video
games). In addition, he had GTCS that occurred every 2 to 3 months
and often progressed to status epilepticus (SE). In the subsequent three
years, he also developed progressive cognitive decline – dementia (Mini
Mental State Examination—MMSE 15) – as well as cerebellar and extra-
pyramidal symptomatology (moderately severe dysarthria, square wave
jerks of extraocular movements, ﬁne tremor of eyelids and lips, truncal
and limb ataxia, bradykinesia, and generally increased muscle tone —
rigidity). The patient's disease was pharmacoresistant, with a seriously
diminished quality of life.
We performed extensive diagnostic evaluation from which we
point out the most important ﬁndings: electroencephalogram revealed
electrographic status epilepticus — paroxysmal discharges of high-
amplitude spike/slowwaves and polyspike/waves almost every second,
more pronounced during photic stimulation; brain magnetic resonance
imaging (MRI) showed diffuse brain atrophy; electromyoneurography
revealed mild generalized myopathy with hypersynchronous poten-
tials, in correlation with myoclonic jerks; cerebrospinal ﬂuid analysis,Fig. 1. Causativemutation for the Lafora body disease in the EPM2B gene c.992delG (homozygou
mutation c.992delG.metabolic tests, and muscle biopsy as well as biopsy of axillary skin
and peripheral nerve studies were normal.
To conﬁrm putative genetic mutation, genomic DNA was extracted
from a peripheral blood sample using a Gentra Puregene Blood DNA pu-
riﬁcation kit (Qiagen Inc., Valencia, CA, USA). The entire coding and
ﬂanking sequences (single exon) of the EPM2B gene were ampliﬁed
by polymerase chain reaction (PCR). Four primer pairs produced four
overlapping PCR fragments spanning the whole EPM2B exon, including
the ﬂanking noncoding sequences (Table 1). The ampliﬁed fragments
were analyzed by agarose gel electrophoresis, puriﬁed using the PCR
Puriﬁcation Kit (Qiagen) and sequenced on a 3730XL DNA Analyzer
(Applied Biosystems). The results were analyzed with the Mutation
Surveyor Software (SoftGenetics). Our analysis identiﬁed causative
mutation for the LBD in the EPM2B gene c.992delG (homozygous)
(Fig. 1). Another polymorphism without clinical relevance was
rs10949483 (homozygous). In order to conﬁrm the detected mutation,
samples from both parents were analyzed. The analysis determined
that both parents were heterozygous carriers of the EPM2B gene muta-
tion c.992delG (Fig. 1).
At that time, the patient was treated with ﬁve antiepileptic
drugs (AEDs): levetiracetam (2500 mg), valproic acid (2000 mg),
metilphenobarbiton (100 mg), clonazepam (4 mg), and acetazolamide
(750 mg), aswell as with L-carnitine. In agreementwith his parents, we
decided to implant a vagus nerve stimulator (Cyberonics; Houston,
Texas, USA). One week after implantation, VNS was initiated at
0.25 mA and gradually increased in the following months to 2 mA.
The duty cycle was on the basis of controlled clinical trials set to a
30-Hz signal frequency, a 500-ms pulse width, 30 s of on-time, and
3 min of off-time [8]. Considering the persistence of myoclonus after
6 months,weperformed a stimulation schemeunderwhich the principal
duty cycle was set to 44% (parameters were gradually changed every
three weeks: ﬁrst, 21 s of on-time and 1.1 min of off-time, then 7 s ofs) demonstrated in the patient. Both parents are heterozygous carriers of the EPM2B gene
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7 s of on-time and 0.3 min of off-time for three months). After VNS
implantation, we did not reduce the dose and number of AEDs. In the
one-year follow-up period, the patient's clinical condition and quality of
life improved. Therewas signiﬁcant regression ofmyoclonus (myoclonus
is less frequent, on a weekly basis, limited to the hands, and no longer
occurs in clusters) and moderate regression of cerebellar symptomatol-
ogy, and, following VNS implantation, the patient did not experience
GTCSs or SE. The patient did not report any signiﬁcant side effects of
the VNS; however, he complained about transient mild hoarseness
after the neurosurgical procedure.
3. Discussion and conclusion
Our case suggests that VNS may have utility in patients with LBD.
The efﬁcacy of adjunctive VNS is well established in adults and adoles-
cents with partial epilepsy with or without secondary generalization,
aswell as in patients with Lennox–Gastaut syndrome [9–11]. According
to the four published cases in the literature so far, VNS has also been
shown to be useful for GTCSs and SE in patients with PMEs — ULD,
MERRF, and Gaucher's disease (with the last disease being a rarer case
of PME). However, in three of those cases, VNS did not control myoclo-
nus, cerebellar symptoms, and mental retardation. Like the patients
studied in the literature, our patient was followed for one year and
beneﬁted fromVNSwithmarked reduction of GTCSs and SE. In addition,
our patient showed reduction of myoclonus and improvement in
cerebellar abnormalities. The explanation could lie not only in the dif-
ferent etiology of PMEs but also in the differences in VNS parameter set-
tings between the patients. In the two recently published cases by A.
Fujimoto et al. [7] (one case with MERRF and one case with Gaucher's
disease), the duty cycle was set to a 30-Hz signal frequency, a 500-ms
pulse width, a 30-second on-time, and a 5-minute off-time. In our
patient with LBD, we managed to reduce the myoclonus by gradually
changing the duty cycle to 7 s of on-time and 0.3 min of off-time
(other parameters such as signal frequency and pulse width were the
same in all three patients). The ﬁnal dosing increments of VNS in our
patient and in the other two patients were 2 mA, 1.25 mA, and 1.5 mA,
respectively.
We want to emphasize the positive effects of VNS for patients with
LBD in reducing GTCSs, status epilepticus, myoclonus, and cerebellar
symptoms. To our knowledge, this is the ﬁrst such reported case.
Vagus nerve stimulation therapy may be considered a treatment option
for the different clinical entities of PME. Further clinical studies with a
larger number of patients are needed to conﬁrm the clinical effects pro-
duced by chronic vagus stimulation in patients with progressive myoc-
lonus epilepsies.Ethics in publishing
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